ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore’s non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled “Non-Invasive Vagus Nerve Stimulation (nVNS) for Adju ...

Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided sele ...

公司动态 - 公司管理层将参加H C Wainwright第27届全球投资会议 会议于2025年9月9日在纽约Lotte New York Palace酒店举行[1] - 公司管理层将在会议期间进行一对一投资者会议[1] - 投资者可通过H C Wainwright销售代表或公司投资者关系邮箱ecor@fnkir.com预约会议[2] 公司业务概览 - 公司处于商业化阶段的生物电子医学与健康技术领域 致力于通过非侵入性生物电子技术改善健康和生活质量[3] - 核心处方产品包括gammaCore非侵入性迷走神经刺激装置和Quell神经刺激器 用于治疗慢性疼痛综合征[3] - 公司商业化产品包括手持式个人健康设备Truvaga和TAC-STIM 用于促进整体健康与人体机能提升[3] 投资者联系信息 - 公司投资者关系电话为(973) 302-9253 邮箱为investors@electrocore.com[4] - 公司官方网站为www.electrocore.com[4]